Quantcast

Latest Immune Design Stories

2014-06-05 08:28:41

In vivo T cell active immunotherapy generated from DCVex(TM) platform SEATTLE and SOUTH SAN FRANCISCO, Calif., June 5, 2014 /PRNewswire/ -- Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVex(TM) lentiviral vector platform....

2014-05-27 08:28:58

SEATTLE and SAN FRANCISCO, May 27, 2014 /PRNewswire/ -- Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced the application of its GLAAS(TM)( )discovery platform in the Phase 1 clinical trial of MEDI7510, an investigational agent for respiratory syncytial virus (RSV) being developed by MedImmune, the global biologics research and development arm of AstraZeneca....

2014-03-18 08:32:23

SEATTLE and SOUTH SAN FRANCISCO, Cali., March 18, 2014 /PRNewswire/ -- Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced the appointment of Franklin M. Berger, CFA to the company's board of directors. http://photos.prnewswire.com/prnvar/20130926/SF87058LOGO Mr. Berger is a major player in the biotechnology industry with more than 25 years of experience in capital...

2014-03-06 08:31:36

SEATTLE and SOUTH SAN FRANCISCO, Calif., March 6, 2014 /PRNewswire/ -- Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced the appointment of biotechnology and pharmaceutical industry veteran William ("Bill") R. Ringo to the company's board of directors. http://photos.prnewswire.com/prnvar/20130926/SF87058LOGO Mr. Ringo brings more than four decades of...

2014-01-27 08:27:54

Trial to evaluate ID-G100 in patients with Merkel cell carcinoma SEATTLE and SOUTH SAN FRANCISCO, Calif., Jan. 27, 2014 /PRNewswire/ -- Immune Design, a clinical-stage biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of ID-G100 in patients with Merkel cell carcinoma (MCC). (Logo: http://photos.prnewswire.com/prnh/20130926/SF87058LOGO)...

2008-06-23 06:00:31

SEATTLE, June 23 /PRNewswire/ -- Immune Design, a new generation vaccine company built on emerging understanding of the human immune system, today announced the closing of an $18 million Series A financing. The current round was co-led by Alta Partners, The Column Group and Versant Ventures. The Column Group initially incubated the Company. "We are pleased and fortunate to have such an outstanding syndicate of investors joining a world class team of experienced founders and scientific...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.